Levocetirizine and Montelukast in an 8-Month-Old Child for Allergic Skin Reaction

Summary Answer

1. Levocetirizine in Infants

• A double-blind study in infants aged 6-11 months (n = 45-69) used levocetirizine 1.25 mg once daily for 2 weeks for allergic rhinitis and chronic idiopathic urticaria - it was well tolerated and safe.
• A long-term 18-month trial in 255 children aged 12-24 months showed a similar safety profile.

• 1.25 mg (oral drops/solution) once daily
• This dose should NOT be exceeded, as it is pharmacokinetically equivalent to the adult 5 mg dose (due to higher weight-adjusted clearance in infants)
• Safety has NOT been established below 6 months of age

• Second-generation H1 antihistamines (including levocetirizine) are first-line for urticaria and allergic skin reactions
• The textbook specifically notes: "Current prescribing manuals should be consulted for details on doses in children"
• Levocetirizine has a plasma half-life of 7-10 hours and is dosed once daily

2. Montelukast in an 8-Month-Old

• Regulatory approval age: Montelukast granules (4 mg) are approved from 6 months in many countries (including India and EU) for asthma prophylaxis. However, its use for allergic skin reactions / urticaria is a different matter.
• For urticaria/skin allergy specifically: Montelukast is classified as a second-line medication in the dermatology textbook (Table 18.6, evidence level 3 = small case series only), indicated specifically for:
  • Aspirin-sensitive urticaria
  • Delayed pressure urticaria
  • Possibly CSU with angioedema (as add-on to antihistamines)
• The standard adult dose is 10 mg/day (from the textbook table). For children 6-23 months, the approved dose is 4 mg granules once daily (for asthma/allergic rhinitis), but this is NOT an approved indication for urticaria at this age.
• Recent evidence (2024, PMID: 38792886) - an observational study of 37 children with chronic urticaria (age range 0-18 years, including infants):

  "Montelukast showed no benefit" in pediatric chronic urticaria. All children were treated with H1-antihistamines as first-line; montelukast was added to some but showed no improvement.

3. What the Dermatology Textbook Says About Children Specifically

"It is unusual for children to need second-line therapies, except the occasional use of prednisolone for very severe acute exacerbations of chronic urticaria."

• Antihistamine (levocetirizine 1.25 mg/day) is the appropriate first-line treatment
• Montelukast is a second-line agent with poor evidence in this age group and recent data showing no benefit in pediatric urticaria

4. Practical Clinical Recommendations

• Levocetirizine oral solution/drops must be used - tablets are not appropriate for this age
• Renal function should be checked before use (use is not recommended in children 6 months - 11 years with kidney disease)
• For an acute allergic skin reaction, a short course of cetirizine (parent compound, equally safe from 6 months, 2.5 mg/day) is also an option - may be more readily available as drops in some settings
• If the reaction is severe (angioedema, anaphylaxis), short-course prednisolone is the appropriate adjunct - not montelukast
• Montelukast combination may be considered only if the skin reaction is part of a broader allergic picture including asthma/rhinitis, and even then, its role in the skin component is unproven